Barclays analyst Etzer Darout initiated coverage of Terns Pharmaceuticals (TERN) with an Overweight rating and $15 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns Pharmaceuticals
- Terns Pharmaceuticals assumed with a Neutral at H.C. Wainwright
- Terns Pharmaceuticals: A Promising Buy Amid Competitor Challenges in the Oral GLP-1 Space
- Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho
- Terns Pharmaceuticals Reports Q2 2025 Financial Results